Derik De Bruin
Stock Analyst at B of A Securities
(3.73)
# 762
Out of 5,130 analysts
222
Total ratings
67.79%
Success rate
16.85%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Buy | $43 → $60 | $54.46 | +10.17% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $148.52 | +11.10% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,485.12 | -6.40% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $238.37 | -7.71% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $39.44 | -31.54% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $104.43 | +5.33% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $20.46 | -36.46% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $48.29 | +4.54% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $396.75 | -5.48% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $6.58 | +67.17% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $102.11 | -36.34% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $13.16 | +21.58% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $618.86 | +6.65% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $242.41 | -3.06% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $220.91 | -4.94% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $275.52 | +28.85% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $21.06 | +23.46% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $251.81 | +7.62% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $174.44 | +4.33% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $17.39 | +20.76% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $18.39 | +74.01% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $141.07 | -29.11% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.87 | +14.87% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.66 | +255.19% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.95 | +233.33% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $181.38 | +43.35% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.24 | +1,198.70% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $127.17 | -5.64% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.33 | +286.27% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $713.35 | -67.06% | 3 | Nov 2, 2018 |
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $54.46
Upside: +10.17%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $148.52
Upside: +11.10%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,485.12
Upside: -6.40%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $238.37
Upside: -7.71%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $39.44
Upside: -31.54%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $104.43
Upside: +5.33%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $20.46
Upside: -36.46%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $48.29
Upside: +4.54%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $396.75
Upside: -5.48%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $6.58
Upside: +67.17%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $102.11
Upside: -36.34%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $13.16
Upside: +21.58%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $618.86
Upside: +6.65%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $242.41
Upside: -3.06%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $220.91
Upside: -4.94%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $275.52
Upside: +28.85%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $21.06
Upside: +23.46%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $251.81
Upside: +7.62%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $174.44
Upside: +4.33%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $17.39
Upside: +20.76%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $18.39
Upside: +74.01%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $141.07
Upside: -29.11%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.87
Upside: +14.87%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.66
Upside: +255.19%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.95
Upside: +233.33%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $181.38
Upside: +43.35%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.24
Upside: +1,198.70%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $127.17
Upside: -5.64%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.33
Upside: +286.27%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $713.35
Upside: -67.06%